NASDAQ:CYTK - Cytokinetics Stock Price, News & Analysis

$12.97
-0.16 (-1.22 %)
(As of 09/18/2019 01:49 PM ET)
Today's Range
$12.87
Now: $12.97
$13.21
50-Day Range
$11.86
MA: $13.25
$14.50
52-Week Range
$5.75
Now: $12.97
$14.94
Volume16,650 shs
Average Volume346,423 shs
Market Capitalization$761.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.50 million
Book Value$0.47 per share

Profitability

Net Income$-106,290,000.00
Net Margins-308.73%

Miscellaneous

Employees130
Market Cap$761.08 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.


Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) released its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.06. The biopharmaceutical company had revenue of $7.14 million for the quarter, compared to analysts' expectations of $6.81 million. Cytokinetics had a negative return on equity of 575.21% and a negative net margin of 308.73%. View Cytokinetics' Earnings History.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Cytokinetics.

What price target have analysts set for CYTK?

6 Wall Street analysts have issued 1-year target prices for Cytokinetics' stock. Their predictions range from $16.00 to $26.00. On average, they expect Cytokinetics' stock price to reach $20.1667 in the next year. This suggests a possible upside of 55.4% from the stock's current price. View Analyst Price Targets for Cytokinetics.

What is the consensus analysts' recommendation for Cytokinetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

What are Wall Street analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:
  • 1. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (9/12/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month and raise our price target from $10 to $14 per share of CYTK primarily driven by increased visibility on the omecamtiv (ome’) programs with the initiation of the P3 METEORIC-HF study and removal of the FORTITUDE-ALS overhang. On Thursday AMC Cytokinetics reported 1Q19 revenue of $8.5M & cash of $177M. Our model projects current cash provides two years of runaway (through 2020), which should include readout of the METEORIC-HF studies." (5/10/2019)
  • 3. HC Wainwright analysts commented, "Valuation and potential impediments to achieving it. We reiterate our Buy rating and $26 target. We highlight that omecamtiv, partnered globally with Amgen, drives the lion’s share of our current valuation (>80%). Reldesemtiv (CK-107) represents the remainder of the contribution to our valuation (10.2% for SMA and 6.3% for ALS) with no contribution from the pipeline, especially CK-274, which is now clinical stage. Our price target is based on our clinical net present value (NPV) model." (5/6/2019)

Has Cytokinetics been receiving favorable news coverage?

Media coverage about CYTK stock has trended negative on Wednesday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cytokinetics earned a news sentiment score of -2.9 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Cytokinetics.

Who are some of Cytokinetics' key competitors?

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (amgn), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), TG Therapeutics (TGTX), Geron (GERN) and Inovio Pharmaceuticals (INO).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.44%), Vanguard Group Inc. (6.86%), Wasatch Advisors Inc. (5.57%), Northern Trust Corp (1.17%), Bank of New York Mellon Corp (1.11%) and Point72 Asset Management L.P. (1.03%). Company insiders that own Cytokinetics stock include Caryn Gordon Mcdowell, Fady Ibraham Malik and Robert I Blum. View Institutional Ownership Trends for Cytokinetics.

Which major investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including South Dakota Investment Council, D. E. Shaw & Co. Inc., Invesco Ltd., Fosun International Ltd, Pinnacle Associates Ltd., Public Employees Retirement System of Ohio, Zacks Investment Management and Ladenburg Thalmann Financial Services Inc.. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.

Which major investors are buying Cytokinetics stock?

CYTK stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Morgan Stanley, Nuveen Asset Management LLC, BlackRock Inc., Vanguard Group Inc., Northern Trust Corp, Renaissance Technologies LLC and Panagora Asset Management Inc.. View Insider Buying and Selling for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $12.98.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $761.67 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.View Additional Information About Cytokinetics.

What is Cytokinetics' official website?

The official website for Cytokinetics is http://www.cytokinetics.com/.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  620 (Vote Outperform)
Underperform Votes:  252 (Vote Underperform)
Total Votes:  872
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel